Mankind Pharma Limited Latest Updates

Strategic Brand Acquisition On March 18, 2026, Mankind Pharma announced the acquisition of the Rivotril brand (clonazepam) from Roche for the Indian market. This acquisition grants Mankind exclusive rights to manufacture, market, and distribute the drug in India. Rivotril is a widely recognized "textbook" brand in the Central Nervous System (CNS) segment, and this move is intended to significantly strengthen Mankind’s chronic therapy portfolio and specialist recall. Entry into Semaglutide Market The company is preparing for an early entry into India’s high-growth semaglutide market, targeting a launch immediately following the drug's patent expiry in late March 2026. By introducing a more affordable generic version of the treatment—which is used for Type-2 diabetes and weight management—Mankind aims to capture early market share in a segment expected to see intense domestic competition. Q3 FY26 Financial Performance For the quarter ended December 31, 2025 (reported in February 2026), Mankind Pharma delivered an 11.5% year-on-year (YoY) increase in revenue, reaching ₹3,567 crore. While net profit rose 9.5% to ₹414 crore, the company faced some margin compression, with adjusted EBITDA margins declining to 25.9% from 27.6%. This squeeze was attributed to increased R&D investments (now 2.9% of sales) and higher employee expenses following a significant field force restructuring. Stock Market Trends The stock has recently experienced a bearish trend, touching a new 52-week low of ₹1,909.70 on March 23, 2026. This downward movement reflects broader market volatility and investor reaction to the recent margin pressure, despite the strong double-digit growth seen in its chronic therapy segments like cardio (up 16.7%) and anti-diabetes (up 14.4%).